Pavel Klener
Overview
Explore the profile of Pavel Klener including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daumova L, Manakov D, Petrak J, Sovilj D, Behounek M, Andera L, et al.
Cell Death Discov
. 2025 Feb;
11(1):65.
PMID: 39966387
A large body of evidence suggests that hypoxia drives aggressive molecular features of malignant cells irrespective of cancer type. Non-Hodgkin lymphomas (NHL) are the most common hematologic malignancies characterized by...
2.
Rataj J, Gorecki L, Muthna D, Sorf A, Krystof V, Klener P, et al.
Biomed Pharmacother
. 2024 Dec;
182():117788.
PMID: 39733588
Acute myeloid leukemia (AML), a heterogeneous hematologic malignancy, has generally a poor prognosis despite the recent advancements in diagnostics and treatment. Genetic instability, particularly mutations in the FMS-like tyrosine kinase...
3.
Golovina E, Kokavec J, Kazantsev D, Yurikova O, Bajecny M, Savvulidi F, et al.
Arch Med Res
. 2024 Nov;
56(3):103124.
PMID: 39591901
Background: Cell cycle progression and leukemia development are tightly regulated processes in which even a small imbalance in the expression of cell cycle regulatory molecules and microRNAs (miRNAs) can lead...
4.
Willis B, Mongeon K, Dry H, Neveras I, Bryan N, Pandya M, et al.
Leukemia
. 2024 Sep;
38(12):2663-2674.
PMID: 39284898
The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-α/δ inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory...
5.
Burda P, Hlavackova A, Polivkova V, Curik N, Laznicka A, Krizkova J, et al.
Mol Metab
. 2024 Aug;
88:102016.
PMID: 39182842
Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A...
6.
Bettazova N, Senavova J, Kupcova K, Sovilj D, Rajmonova A, Andera L, et al.
Blood Adv
. 2024 Aug;
8(20):5279-5289.
PMID: 39158100
Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL) is characterized by recurrent genetic alterations of important regulators of the phosphoinositol-3-kinase (PI3K) cascade including PIK3CA gains...
7.
Faltusova K, Bajecny M, Heizer T, Paral P, Chen C, Szikszai K, et al.
Front Immunol
. 2024 Jul;
15:1405210.
PMID: 38947315
In bone marrow transplantation (BMT), hematopoiesis-reconstituting cells are introduced following myeloablative treatment, which eradicates existing hematopoietic cells and disrupts stroma within the hematopoietic tissue. Both hematopoietic cells and stroma then...
8.
Cabaud Gibouin V, Durand M, Boudesco C, Hermetet F, Nozickova K, Chassagne-Clement C, et al.
Leukemia
. 2024 Jun;
38(8):1742-1750.
PMID: 38906964
Activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL) is driven by aberrant activation of the B-cell receptor (BCR) and the TLR/MyD88 signaling pathways. The heat-shock protein HSP110 is a candidate for...
9.
Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen C, et al.
Blood Adv
. 2024 May;
8(13):3532-3543.
PMID: 38713893
Venetoclax (VEN), a B-cell lymphoma 2 (BCL2) inhibitor, has a promising single-agent activity in mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), and large BCLs, but remissions were generally short,...
10.
Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, et al.
Exp Hematol Oncol
. 2024 Mar;
13(1):34.
PMID: 38528594
Background: Mantle cell lymphoma (MCL) is a chronically relapsing malignancy with deregulated cell cycle progression. We analyzed efficacy, mode of action, and predictive markers of susceptibility to palbociclib, an approved...